Audacious Alpha TAT Programs
Metastatic cancers (pan-tumor focus)
Preclinical/Early ClinicalActive
Key Facts
Indication
Metastatic cancers (pan-tumor focus)
Phase
Preclinical/Early Clinical
Status
Active
Company
About Curadel Pharma
Curadel Pharma is an innovator in radiopharmaceuticals, pioneering a novel 'Audacious Alpha' platform based on zwitterionic chemistry to create targeted alpha therapies with an improved therapeutic window. Its technology is designed to minimize off-target toxicity and prevent tumor resistance, addressing key limitations of current radiotherapies. The company has a Phase 3 program for an optical imaging agent (ZW800-1) and is advancing its early-stage oncology pipeline with $10.5M in Series A2 funding. Led by a team with deep expertise in zwitterionicity and drug development, Curadel aims to redefine outcomes in challenging metastatic cancers.
View full company profile